Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.
about
Prolonged overall survival in gastric cancer patients after adoptive immunotherapyThe transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.Immunotherapy using dendritic cells against multiple myeloma: how to improve?Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
P2860
Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@ast
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@en
type
label
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@ast
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@en
prefLabel
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@ast
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@en
P2860
P1476
Dendritic cell immunotherapy f ...... lymphoma and multiple myeloma.
@en
P2860
P304
P356
10.1046/J.1440-1711.1999.00859.X
P577
1999-10-01T00:00:00Z